Stock IMNN IMUNON, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Imunon, Inc.

Equities

IMNN

US15117N6022

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 04:00:00 2025-01-17 pm EST 		5-day change 1st Jan Change
0.9131 USD +1.68% Intraday chart for Imunon, Inc. +1.47% -3.88%
Dec. 19 IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer CI
Dec. 10 Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001 CI

Press Releases

Search
See the results
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
Dec. 19
 AQ
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
Dec. 10
 AQ
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
Nov. 25
 AQ
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
Nov. 07
 AQ
IMUNON : Reports Third Quarter 2024 Financial Results and Provides Business Updates Form 8 K
Nov. 07
 PU
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
Nov. 07
 AQ
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
24-10-31
 AQ
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
24-10-30
 AQ
IMUNON : Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Form 8 K
24-10-07
 PU
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
24-10-07
 AQ
IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
24-09-10
 AQ
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
24-09-09
 AQ
IMUNON to Host R&D Day on September 18th
24-08-28
 AQ
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
24-08-14
 AQ
IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
24-08-07
 AQ
IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
24-07-31
 AQ
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
24-07-30
 AQ
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
24-07-29
 AQ
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
24-06-24
 AQ
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
24-06-05
 AQ
Imunon : Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting entitled “A Phase II Study Evaluating the effect of IMNN-001 on Second Look Laparoscopy (SLL) when Administered in Combination with Bevacizumab (BEV) and Neoadjuvant Chemother
24-06-03
 PU
Imunon : Management Change/Compensation - Form 8-K
24-05-20
 PU
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
24-05-15
 AQ
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
24-05-13
 AQ
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
24-05-13
 AQ
Become a member to access more news.
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMNN Stock
  4. News Imunon, Inc.
  5. Press Releases